David, Dolores D.
HRN: 21-50-11 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/29/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
08/29/2022
09/05/2022
IV
600mg
Q8
Infected Breast Ca
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes